Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Clinical and Virologic Outcomes in COVID-19 Patients With Chronic Kidney Disease Treated With Nirmatrelvir-ritonavir

NCT05624840 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT05624840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05624840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Clinical and Virologic Outcomes in COVID-19 Patients With Chronic Kidney Disease Treated With Nirmatrelvir-ritonavir
Lead sponsor
Chinese University of Hong Kong
Phase
Observational
Overall status
Completed
Start date
November 7, 2022
Completion date
February 1, 2023
Enrollment
85 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronc kidney disease stage 5, chronic kidney disease stage4, covid-19